Full Press Release Details
argenx Appoints Camilla
Sylvest to Board of Directors
Amsterdam, the Netherlands - argenx (Euronext & Nasdaq:
ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that
during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive
director to its Board of Directors.
Mrs. Sylvest brings strong strategic and operational leadership
in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting
result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
argenx is a global immunology company committed to improving the lives
of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program
(IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed
and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. The Company is
evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its